Role of MR Imaging and FDG PET/CT in Selection and Follow-up of Patients Treated with Pelvic Exenteration for Gynecologic MalignanciesThe value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration.Developments in nuclear magnetic resonance imaging and spectroscopy: application to radiation oncology.Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy.Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer.Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy.Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of referenceImaging of hypoxia-driven gene expression in an orthotopic liver tumor model.New treatments for localized prostate cancer.Functional magnetic resonance imaging in prostate cancer.Imaging of lymph node micrometastases using an oncolytic herpes virus and [F]FEAU PET.Imaging hypoxia in orthotopic rat liver tumors with iodine 124-labeled iodoazomycin galactopyranoside PET.Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations.Molecular Imaging of Prostate CancerAre histopathological features of prostate cancer lesions associated with identification of extracapsular extension on magnetic resonance imaging?The expanding landscape of diffusion-weighted MRI in prostate cancerAssessment of Prostate Cancer Aggressiveness by Use of the Combination of Quantitative DWI and Dynamic Contrast-Enhanced MRI.Advances in magnetic resonance imaging: how they are changing the management of prostate cancer.Imaging Features of Uncommon Gynecologic CancersImaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene.Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI.Semi-automatic deformable registration of prostate MR images to pathological slicesMRI-Safe Robot for Endorectal Prostate Biopsy.Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.What do we expect from imaging?Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness.Improving communication of diagnostic radiology findings through structured reportingA multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.Advances in imaging in the postoperative patient with a rising prostate-specific antigen level.Thoracic metastasis in advanced ovarian cancer: comparison between computed tomography and video-assisted thoracic surgery.Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study.Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancerPattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomyNormal central zone of the prostate and central zone involvement by prostate cancer: clinical and MR imaging implications.Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI.Value of the hemorrhage exclusion sign on T1-weighted prostate MR images for the detection of prostate cancerImaging of transposed ovaries in patients with cervical carcinoma.Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.Molecular MR imaging in oncology.Indeterminate ovarian mass at US: incremental value of second imaging test for characterization--meta-analysis and Bayesian analysis.
P50
Q28088565-3C9898DA-CFF9-4BA8-8AAF-0944C9BA0262Q30584396-409B97A0-7D64-4DCE-AA81-D9B41BA4BC5BQ30623978-19C7B042-3780-472F-8C5E-693DDAA5D816Q30886781-E1566DB1-4AC4-4340-9933-1570779B0268Q30975500-C30133BA-8E5B-4857-9CBE-2C5E6EB0092BQ30983669-69763A9E-87EB-4D2F-AFD1-BBD346DF4B2FQ30995961-36145979-40E6-4410-AD0E-603DEDAFFC87Q33305338-08504801-1517-4830-B560-EA56968FE7D8Q33394465-3FC2A586-9336-4950-AFCB-C26542674320Q33404776-B6951CCB-7922-4670-837C-9C13A799F32AQ33416415-28B9577C-8705-47B8-B9D7-064487D0171DQ33555278-BB69E233-CF73-4481-947A-CE16E4A67349Q33570946-9900927E-F062-491A-970E-278154205165Q33620520-D8315AF7-9BC0-405B-8E04-54EB541C13D1Q33699276-47520F16-3E2D-4A27-A1CB-2FB212370FDDQ33762501-1369D390-63A0-4D8A-B1BE-EA8B720A557BQ33821885-529A0DCA-A568-4749-A875-D3E5E0DAA331Q33834982-242D051A-CA3E-4B63-B309-EE196FF75D46Q33886628-B42866C3-7B69-460E-B18C-90C1770FA779Q33887850-AED04ACE-D54E-4CAA-ACDC-78AE95AD191CQ33940082-EDA97DD8-D09D-4498-A189-4F05E16A4E8FQ34286215-68DDA770-15A3-4B61-965A-4FE46A0123CDQ34448754-BE9DF69F-24DC-4FFE-AF4E-053E416A9353Q34681161-62E7CDF7-E344-4F23-9AC7-3163EDBEE35BQ34738204-0952232F-9A37-46A3-A0C4-A25E5BD7F294Q34995967-62E8C6BC-6F58-40C9-A07E-AD7F17E5DF2BQ35062105-EC9C8320-FF54-4040-B86E-9F37A17AB005Q35294575-17814C4D-CB6B-4295-A93F-B42EBAA79EBFQ35565205-A17FACAC-FA24-44BD-B9B9-12679DEB6B7CQ35663648-EF3CDAE2-1FB7-46FF-9DA0-886C18AC9CDAQ35683375-3DD154AA-A609-442B-852D-3D66771F54C9Q35722781-7C2740B0-CFC3-47FD-A731-9841867F3A8AQ35748251-032A4E1C-8BA4-4E0D-9307-67CA9BCEF9F5Q35773547-587BD1D8-09A3-4E59-8972-0D15441A98E3Q35931475-84120ED0-0FC5-480D-A33A-0BD3E06F8BA2Q35985579-C9EEE32C-8B84-424D-AF5B-AB2406D9CF02Q36108212-CD48FE00-A306-43C5-8FA6-868443DB773EQ36132602-185D8FE1-F27E-4747-A93E-CBD1E368FD30Q36151202-B558E482-CDF6-4648-92C0-3074B49D54ACQ36163024-53363E01-530B-4D03-88F9-AE1005D14914
P50
description
Amerikaans radiologe
@nl
radiologist
@en
إشعاعاتية من الولايات المتحدة الأمريكية
@ar
name
Hedvig Hricak
@ast
Hedvig Hricak
@ca
Hedvig Hricak
@de
Hedvig Hricak
@en
Hedvig Hricak
@es
Hedvig Hricak
@fr
Hedvig Hricak
@hr
Hedvig Hricak
@nl
Hedvig Hricak
@sl
type
label
Hedvig Hricak
@ast
Hedvig Hricak
@ca
Hedvig Hricak
@de
Hedvig Hricak
@en
Hedvig Hricak
@es
Hedvig Hricak
@fr
Hedvig Hricak
@hr
Hedvig Hricak
@nl
Hedvig Hricak
@sl
prefLabel
Hedvig Hricak
@ast
Hedvig Hricak
@ca
Hedvig Hricak
@de
Hedvig Hricak
@en
Hedvig Hricak
@es
Hedvig Hricak
@fr
Hedvig Hricak
@hr
Hedvig Hricak
@nl
Hedvig Hricak
@sl
P69
P1006
P1015
P214
P227
P244
P268
P269
P349
P1006
P1015
P106
P1207
n2003030332